FKGK 18

An inhibitor of GVIA iPLA2

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥2037.00

1630.00

- +
10mg

￥3862.00

3090.00

- +
25mg

￥8650.00

6920.00

- +
50mg

￥14087.00

11270.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci71584
CAS: 1071001-09-6
别名:
分子式: C16H15F3O
分子量: 280.3
纯度: >98%
溶解度: DMF: 20 mg/ml,DMSO: 20 mg/ml,PBS (pH 7.2): 2 mg/ml
储存: Store at -20°C
库存: 现货

Background

FKGK 18 is an inhibitor of group VIA (GVIA) calcium-independent phospholipase A2 (iPLA2). It inhibits GVIA iPLA2 by 99.9% at 0.091 mole fraction in a mixed micelle activity assay and is selective for GVIA iPLA2 over GIVA cPLA2 and GV sPLA2 where it shows 80.8 and 36.8% inhibition, respectively. FKGK 18 inhibits iPLA2β activity in cytosolic extracts from INS-1 cells overexpressing iPLA2β (IC50 = ~50 nM) as well as iPLA2γ activity in mouse heart membrane fractions (IC50s = ~1-3 μM). It inhibits glucose-induced increases in prostaglandin E2 production and insulin secretion in human pancreatic islets when used at a concentration of 10 μM and inhibits thapsigargin-induced apoptosis in INS-1 cells overexpressing iPLA2β in a concentration-dependent manner. FKGK 18 (20 mg/kg, 3 times per week) reduces blood glucose levels in an intraperitoneal glucose tolerance test, decreases the incidence of diabetes, and increases serum insulin levels in non-obese diabetic (NOD) mice.